Sign In

Patents and Recent Publications


US Patent Application Number: 15935155. TITLE OF THE INVENTION: Discovery of NOVEL First-In-Class HETEROCYCLIC SYSTEMS for the treatment of Multidrug Resistant Superbugs. Filed on March 2018. RAM confirmation Number: 032618INTEFSW10523900. EFS ID: 32151250. Inventors: Dr. Taleb AlTel; Dr Vunnam Srinivasulu; Dr. Farah ElMarzooq; Dr Rafat El-Awady.

Summary of the Invention: The present disclosure relates to novel imidazole fused polycyclic systems, methods for their use, and processes for their preparation. The compounds of the present disclosure are particularly useful against a variety of bacteria, including multidrug resistant strains of Staphylococcus aureus, S. saprophyticus, S. haemolyticus, and S. epidermidis.

US Patent Application Number: 15935120; TITLE OF THE INVENTION: Discovery of NOVEL First-In-Class HETEROCYCLIC SYSTEMS for the treatment of Cancer. Filed in March 2018. RAM confirmation Number: 032618INTEFSW10050600 EFS ID:  32150635. Inventors: Dr. Taleb AlTel; Dr Rafat El-Awady; Dr Vunnam Srinivasulu; Dr Cijo George Vazhappilly; Dr Hany Omar.

Summary of the Invention: This disclosure relates to novel antitumor agents, pharmaceutically acceptable salts thereof, as well as processes of manufacture, and medicaments containing such compounds. The presently disclosed compounds have anticancer activity, which results in reduction of tumor cell proliferation, induction of apoptosis, as well as DNA damage. This present disclosure also concerns the use of the disclosed compounds in relation to the enzymes thioredoxin reductase, transketolase, cytosol aminopeptidase, glutathione reductase, inositol-3-phosphate synthase, and transferrin receptor activities in addition to regulation of these enzymes.

US Patent Application Number: 62/711,401. TITLE OF THE INVENTION: Discovery of Novel First-In-Class Nature-Inspired Compounds targeting the mitochondrial function and pharmaceutical composition thereof as novel treatment for cancer immunotherapy. Filed May 2018. Inventors: Dr. Taleb AlTel; Dr Vunnam Srinivasulu; Dr. Saleh Ibrahim; Dr. Paul Schilf.

Summary of the Invention:This invention relates to novel antitumor agents and pharmaceutically acceptable salts thereof, processes for the manufacture of these novel constrained cyclic frameworks as defined in the specifications of general formulas and medicaments containing such compounds. This invention also concerns the use of such compounds to modulate the cellular mitochondrial functions by measuring the ATP content, the mitochondrial membrane potential and the cellular redox potential as well as their toxicities and effects on T and B cells.

RIMHS-Examples of Recent publications:

GBD 2019 Universal Health Coverage Collaborators, Saddik B. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study. The Lancet; in press; available online 27 August 2020.

Orphan G-protein coupled receptor 183 (GPR183) potentiates insulin secretion and prevents glucotoxicity-induced β-cell dysfunction. Taneera J, et al.Mol Cell Endocrinol. 2020 Jan 1;499:110592. doi: 10.1016/j.mce.2019.110592.PMID: 31550518. 

Mc Namara KP, et al. Implementing screening interventions in community pharmacy to promote interprofessional coordination of primary care – A mixed methods evaluation. Res Social Adm Pharm. 2020 Feb;16(2):160-167. doi: 10.1016/j.sapharm.2019.04.011.

Alzubaidi H, et al. Critical Role of Pharmacists in Caring for Alzheimer's Disease Patients. J Alzheimers Dis. 2020;73(3):1253-1264. doi: 10.3233/JAD-190804.

Bani issa et al., (2020). Obesity and its determinants in adolescent population: a comparison study of private and public schools. BMJ open (awaiting final decision)

Hamad M, Khuloud Bajbouj, Jalal Taneera.  2020. The case for an estrogen-iron axis in health and disease.  Experimental and Clinical Endocrinology & Diabetes, doi: 10.1055/a-0885-1677.

Li M, et al. Melatonin sensitises shikonin-induced cancer cell death mediated by oxidative stress via inhibition of the SIRT3/SOD2-AKT pathway. Redox Biol. 2020 Jul 2;36:101632. doi: 10.1016/j.redox.2020.101632. PMID: 32863233

MT Al Bataineh, et al.  2020.  Revealing links between gut microbiome and its fungal community in Type 2 Diabetes Mellitus among Emirati subjects: A pilot study.  Scientific reports 10 (1), 1-11

Alsohime F, et al JAK inhibitor therapy in a child with inherited USP18 deficiency. New England Journal of Medicine. 2020 Jan;382(3):256-65 (IF: 70.6).

Martin-Fernandez M, et al. Systemic Type I IFN Inflammation in Human ISG15 Deficiency Leads to Necrotizing Skin Lesions. Cell Reports. 2020 May;31(6):107633 (IF: 8.1).

Han L, et al. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica. 2020 Mar;105(3):697-707.

Alfarouk KO, et al. The Pentose Phosphate Pathway Dynamics in Cancer and Its Dependency on Intracellular pH. Metabolites. 2020;10(7):285. Published 2020 Jul 11. doi:10.3390/metabo10070285

Understanding the Role of Innate Immune Cells and Identifying Genes in Breast Cancer Microenvironment. Shihab I, et al. Cancers (Basel). 2020 Aug 9;12(8):E2226. doi: 10.3390/cancers12082226.


Sharjah Institute for Medical Research Publications Statistics 2015-2018